Show Notes
For over a decade, sorafenib remained unchallenged as first-line therapy for hepatocellular carcinoma, based on the SHARP trial, which showed survival increasing from 7.9 to 10.7 months. This demonstrated modest efficacy in a disease notoriously resistant to systemic treatment. That drought broke in 2020, when IMbrave150 demonstrated that atezolizumab plus bevacizumab beat sorafenib outright, pushing median survival past 19 months and putting immunotherapy on the map for liver cancer. Two years later, HIMALAYA proved that a single priming dose of anti-CTLA-4 could unlock durable responses, with the STRIDE regimen nearly doubling five-year survival compared with sorafenib. Then IMbrave050 asked whether that success could move earlier, into the adjuvant setting after resection — and the early promise didn’t hold up on longer follow-up. Together, these three trials mark both immunotherapy’s arrival in liver cancer and the limits of assuming it translates cleanly across settings.
Trials Discussed on Today's Episode: HIMALAYA Trial IMbrave 050 IMbrave 150
For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected]
Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.
Hosted on Acast. See acast.com/privacy for more information.
More from Oncology for the Inquisitive Mind
Last week Josh and Michael discussed early ovarian cancer, but as is always the case many patients either do not respond completely to treatment of their early disease or present with advanced disease and thus are robbed of that chance. In these patients, getting the treatment right is a complex discussion but a vital one. In this episode, we discuss two studies in the advanced ovarian cancer space, a space that could still use more love, but has seen developments in recent years.
Our Back to Basics odyssey nears its end, a journey just as epic as Matt Damon's (we think so, anyway). As we enter the final stretch, we discuss ovarian cancer, a cancer with significant mortality and morbidity despite advances in treatment. In this episode Josh and Michael discuss two studies in the early ovarian cancer space, a topic fraught with challenges as unique as Scylla and Charybdis.
On this episode, Josh and Michael examine the treatment of advanced melanoma, the condition that blazed the trail for immunotherapy to change the face of cancer treatment. However, immunotherapy is not the ONLY treatment for melanoma, as a significant proportion of cases also harbour a BRAF mutation. So, if you have someone with such an example, what do you do? How would you sequence your treatment? This question, and a reflection on the incredible beginnings of immunotherapy is coming to you on today's episode.
Our guest today is someone whose work touches almost every corner of oncology: from the exam room to the lab to the systems we work within.
In this episode, Michael and Josh delve into the world of early melanoma. Some may think that melanoma has had its moment in the sun (pun slightly intended) and that other cancer treatments are passing it by. But in this instance, you can teach an old dog new tricks, an old immunotherapy dog, to be precise. In addition, one of today's studies has Michael's favourite design of any trial: see if you can figure out which one!